SAMHD1是基于抗代谢物的癌症治疗的一个障碍。
SAMHD1 is a barrier to antimetabolite-based cancer therapies.
作者信息
Rudd Sean G, Schaller Torsten, Herold Nikolas
机构信息
Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet , Stockholm, Sweden.
Department of Infectious Diseases, Virology, University Hospital Heidelberg , Heidelberg, Germany.
出版信息
Mol Cell Oncol. 2017 Feb 3;4(2):e1287554. doi: 10.1080/23723556.2017.1287554. eCollection 2017.
The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-CTPase that protects cancer cells from cytarabine-induced toxicity. Therefore, we propose targeting SAMHD1 as a strategy to potentiate cytarabine and possibly other antimetabolite-based therapies.
急性髓系白血病（AML）治疗的结果取决于白血病原始细胞积累阿糖胞苷（ara-C）的活性三磷酸形式阿糖胞苷三磷酸（ara-CTP）的倾向。我们鉴定出含无菌α基序和HD结构域蛋白1（SAMHD1）为一种阿糖胞苷三磷酸酶，它可保护癌细胞免受阿糖胞苷诱导的毒性作用。因此，我们建议将SAMHD1作为一种增强阿糖胞苷以及可能其他基于抗代谢物疗法疗效的策略。
Zotero 插件